Unraveling the immune microenvironment in primary CNS lymphoma

Area of Science:

• Neuro-oncology
• Immunology
• Malignant Lymphoid Conditions

Background:

• Primary central nervous system lymphoma (PCNSL) is a rare malignancy within the immune-privileged central nervous system.
• PCNSL biology is intricately linked to its immune microenvironment, involving cells like lymphocytes, macrophages, and dendritic cells.
• An immunosuppressive microenvironment correlates with poor survival, while T-cell immunity is crucial for favorable outcomes.

Purpose of the Study:

• To explore the complex interplay between the PCNSL tumor microenvironment and disease progression.
• To highlight the prognostic and therapeutic significance of immune biomarkers in PCNSL.
• To advocate for the integration of immune insights into PCNSL risk stratification and treatment strategies.

Main Methods:

• Review of current understanding of PCNSL immunology and microenvironment.
• Analysis of treatment outcomes in relation to immune cell populations and cytokine profiles.
• Evaluation of existing prognostic models and their limitations regarding immune factors.

Main Results:

• High-dose methotrexate-based regimens show curative potential, with up to 70% survival at seven years.
• Relapse rates remain significant, driving interest in immunotherapeutic approaches like checkpoint inhibitors and CAR T-cells.
• The immune-privileged CNS presents challenges for immune surveillance and therapeutic efficacy.

Conclusions:

• The immune microenvironment is a critical determinant of PCNSL progression and patient survival.
• Established prognostic models for PCNSL lack immune biomarkers, necessitating their inclusion.
• Integrating immune biomarkers with novel immunotherapies holds promise for improving PCNSL patient outcomes and care.